Table 7.
Logistic analysis of adverse events for ORR during treatment in all patients.
| Risk factors | Univariable | P value | Multivariable | P value |
|---|---|---|---|---|
| HR (95% CI) | Adjusted HR (95% CI) | |||
| Leucopenia | 0.461 (0.036–5.890) | 0.551 | ||
| Thrombocytopenia | 0.677 (0.086–5.307) | 0.710 | ||
| Lymphopenia | 0.493 (0.080–3.033) | 0.445 | ||
| Anemia | 0.335 (0.060–2.084) | 0.251 | ||
| Elevated ALT | 2.420 (0.398–14.734) | 0.338 | ||
| Elevated AST | 0.162 (0.007–3.629) | 0.251 | ||
| Elevated GGT | 3.355 (0.195–57.720) | 0.404 | ||
| Elevated TBIL | 0.936 (0.145–6.052) | 0.945 | ||
| Hypothyroidism | 0.236 (0.029–1.889) | 0.174 | ||
| Hand–foot syndrome | 1.004 (0.152–6.618) | 0.997 | ||
| Rash | 9.420 (1.213–73.189) | 0.032# | 4.382 (1.297–14.803) | 0.017* |
| RCCEP | 8.236 (0.186–364.788) | 0.276 | ||
| Urine protein | 0.053 (0.004–0.645) | 0.021# | ||
| Muscle soreness | 0.655 (0.019–22.765) | 0.815 | ||
| Diarrhea | 0.145 (0.013–1.611) | 0.116 | ||
| Poor appetite | 0.259 (0.029–2.322) | 0.228 | ||
| Gingival bleeding | 5.497 (0.311–97.185) | 0.245 |
#p < 0.1, *p < 0.05.
ALT, alanine aminotransferase; AST, aspartic aminotransferase; GGT, γ- glutamyl transpeptidase; TBIL, total bilirubin; RCCEP, reactive cutaneous capillary endothelial proliferation.